Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States

References

• McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36:259–73. doi:10.1007/s10935-015-0394-3.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Portnoy A, Getaneh H, Clark S, Knoll M, Bishai D, Yang HK, Patwardhan PD. Modeling the economic burden of adult vaccine-preventable diseases in the United States. Health Aff (Millwood). 2016;35:2124–32. doi:10.1377/hlthaff.2016.0462.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Immunization Schedule for Adults (19 Years of Age and Older). [accessed 2019 Jan 15]. https://www.cdc.gov/vaccines/schedules/hcp/adult.html
   Google Scholar
• Centers for Disease Control and Prevention. Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. [accessed 2019 Jan 15]. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2016.html
   Google Scholar
• Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatrics. 2017;17(1):30. doi:10.1186/s12877-017-0420-9.
   PubMedGoogle Scholar
• Wroe PC, Finkelstein JA, Ray GT, Linder JA, Johnson KM, Rifas-Shiman S, Moore MR, Huang SS. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589–92. doi:10.1093/infdis/jis240.
   PubMed Web of Science ®Google Scholar
• Deiss RG, Arnold JC, Chen W-J, Echols S, Fairchok MP, Schofield C, Danaher PJ, McDonough E, Ridoré M, Mor D, et al. Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. Vaccine. 2015;33(51):7160–67. doi:10.1016/j.vaccine.2015.11.004.
   PubMed Web of Science ®Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74:1231–38.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WWB, Zhang JH, Chan ISF, Yeh -S-S, Levin MJ, Harbecke RM, et al. Effect of a zoster vaccine on herpes zoster–related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58:1634–41. doi:10.1111/j.1532-5415.2010.03021.x.
   PubMed Web of Science ®Google Scholar
• Barlow RS, Reynolds LE, Cieslak PR, AD S. Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, oregon, 2010–2012. Clin Infect Dis. 2014;58:1523–29. doi:10.1093/cid/ciu156.
   PubMed Web of Science ®Google Scholar
• United States Census Bureau. Projected Population by Age, Sex, Race, and Hispanic Origin: 2014 to 2060 [accessed 2019 Jan 15]. https://www.census.gov/data/datasets/2014/demo/popproj/2014-popproj.html
   Google Scholar
• Acosta A. Cost-effectiveness of pertussis vaccine substitution for tetanus booster in prevention of pertussis in adults 65 years and older. Presentation to the Advisory Committee on Immunization Practices (ACIP). Atlanta (GA): US Department of Health and Human Services, CDC; 2012.
   Google Scholar
• Chen -C-C, Balderston McGuiness C, Krishnarajah G, Blanchette CM, Wang Y, Sun K, Buck PO. Estimated incidence of pertussis in people aged <50 years in the United States. Hum Vaccin Immunother. 2016;12:2536–45. doi:10.1080/21645515.2016.1186313.
   PubMed Web of Science ®Google Scholar
• Havers FP, Cho BH, Walker JW,SH. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States. Vaccine. 2020;38:380–87. doi:10.1016/j.vaccine.2019.09.104.
   PubMed Web of Science ®Google Scholar
• Masseria C, Krishnarajah G. The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010. BMC Infect Dis. 2015;15:534. doi:10.1186/s12879-015-1269-1.
   PubMed Web of Science ®Google Scholar
• Millier A, Aballea S, Annemans L, Toumi M, Quilici S. A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev Pharmacoecon Outcomes Res. 2012;12:71–94. doi:10.1586/erp.11.94.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Influenza vaccination coverage estimates for persons 6 months and older by state, HHS region, and the United States, National Immunization Survey-Flu (NIS-Flu) and Behavioral Risk Factor Surveillance System (BRFSS), 2010-11 through 2016-17 influenza seasons. 2017. [accessed 2018 Feb 20]. https://www.cdc.gov/flu/fluvaxview/reportshtml/trends/index.html
   Google Scholar
• Centers for Disease Control and Prevention. AdultVaxView, Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. 2018. [accessed 2018 Feb 20]. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/NHIS-2016.html
   Google Scholar
• Adams DA, Thomas KR, Jajosky RA, Foster L, Baroi G, Sharp P, Onweh DH, Schley AW, Anderson WJ, for the Nationally Notifiable Infectious Conditions Group. Summary of Notifiable Infectious Diseases and Conditions — united States, 2015. MMWR Morb Mortal Wkly Rep. 2017;64:1–143. doi:10.15585/mmwr.mm6453a1.
   PubMed Web of Science ®Google Scholar
• Bresee J, Reed C, Kim IK, Finelli L, Fry A, Chaves SS, Burns E, Gargiullo P, Jernigan D, Cox N, et al. Estimated influenza illnesses and hospitalizations averted by influenza vaccination — United States, 2012–13 influenza season. MMWR Morb Mortal Wkly Rep. 2013;62:997–1000.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae. 2013. Atlanta (GA): Centers for Disease Control and Prevention; 2013.
   Google Scholar
• Centers for Disease Control and Prevention. Estimated Influenza Illnesses and Hospitalizations Averted by Vaccination — United States, 2014–15 Influenza Season. 2015. [accessed 2016 Apr 20]. http://www.cdc.gov/flu/about/disease/2014-15.htm
   Google Scholar
• Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States. 2017. [accessed 2019 Mar 28]. https://www.cdc.gov/flu/about/disease/2015-16.htm
   Google Scholar
• Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15(1):502. doi:10.1186/s12879-015-1262-8.
   PubMedGoogle Scholar
• Kostova D, Reed C, Finelli L, Cheng P-Y, Gargiullo PM, Shay DK, Singleton JA, Meltzer MI, Lu P-J, Bresee JS. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. PLoS One. 2013;8(6):e66312–e. doi:10.1371/journal.pone.0066312.
   PubMed Web of Science ®Google Scholar
• Reed C, Kim IK, Singleton JA, Chaves SS, Flannery B, Finelli L, Fry A, Burns E, Gargiullo P, Jernigan D, et al. Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(49):1151–54.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901–08. doi:10.1007/s11606-016-3651-0.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26(38):4947–54. doi:10.1016/j.vaccine.2008.07.016.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387–94. doi:10.1016/S2213-2600(14)70032-3.
   PubMed Web of Science ®Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Past Seasons Vaccine Effectiveness Estimates 2018. [accessed 2019 Dec 12]. https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html
   Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2013.
   Google Scholar
• Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–45. doi:10.1016/j.vaccine.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Kamiya H, Cho B-H, Messonnier ML, Clark TA, Liang JL. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. Vaccine. 2016;34(15):1832–38. doi:10.1016/j.vaccine.2016.02.027.
   PubMed Web of Science ®Google Scholar
• Chen J, O’Brien MA, Yang HK, Grabenstein JD, Dasbach EJ. Cost-effectiveness of pneumococcal vaccines for adults in the United States. Adv Ther. 2014;31(4):392–409. doi:10.1007/s12325-014-0115-y.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–09. doi:10.1093/cid/ciu918.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307(8):804–12. doi:10.1001/jama.2012.169.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2017 Behavioral risk factor surveillance system survey data and documentation. [accessed 2019 Jan 15]. https://www.cdc.gov/brfss/annual_data/annual_2017.html
   Google Scholar
• Zostavax prescribing information. [accessed 2019 Jan 15]. https://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP: vaccine-specific recommendations (by date published). 2019. [accessed 2020 Jan 14]. https://www.cdc.gov/vaccines/hcp/acip-recs/recs-by-date.html
   Google Scholar
• Kim DK, Riley LE, Hunter P, on behalf of the Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Ann Intern Med. 2018;168:210–20. doi:10.7326/M17-3439.
   PubMed Web of Science ®Google Scholar
• Shingrix prescribing information. [accessed 2019 Jan 15]. https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF
   Google Scholar
• Patterson BJ, Cheng WY, Trofa AF, Duchesneau A, Macheca M, Masseria C, Duh MS A claims-based analysis of hepatitis A, B and A/B vaccination series completion and compliance among US adults. ISPOR 22nd Annual International Meeting. Boston, MA, USA, 2017.
   Google Scholar
• Arias E, Heron M, Xu J. United States life tables, 2014. Natl Vital Stat Rep. 2017;66.
   Google Scholar
• Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. 2019;22:501–08. doi:10.1080/13696998.2018.1542520.
   PubMed Web of Science ®Google Scholar
• Weisbrod BA. The Valuation of Human Capital. J Polit Econ. 1961;69:425–36. doi:10.1086/258535.
   Web of Science ®Google Scholar
• U.S. Department of Health & Human Services. National Adult Immunization Plan. 2016. [accessed 2019 April 10]. https://www.hhs.gov/sites/default/files/nvpo/national-adult-immunization-plan/naip.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Strategies for Increasing Adult Vaccination Rates. 2016. [accessed 2019 Mar 7]. https://www.cdc.gov/vaccines/hcp/adults/for-practice/increasing-vacc-rates.html
   Google Scholar
• Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19–35 months — United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:1123–28. doi:10.15585/mmwr.mm6740a4.
   PubMed Web of Science ®Google Scholar
• Shen AK, Warnock R, Selna W, MaCurdy TE, Chu S, Kelman JA. Vaccination among Medicare-fee-for service beneficiaries: characteristics and predictors of vaccine receipt, 2014–2017. Vaccine. 2019;37:1194–201. doi:10.1016/j.vaccine.2019.01.010.
   PubMed Web of Science ®Google Scholar
• Akinbosoye OETM, Grana J, Macpherson C. Factors associated with zostavax abandonment. Am J Pharm Benefits. 2016;8:84–89.
   Web of Science ®Google Scholar
• Tao Z, Li Y, Stemkowski S, Johnson KD, Acosta CJ, Zhang D, Fendrick AM. Impact of out-of-pocket cost on herpes zoster vaccine uptake: an observational study in a medicare managed care population. Vaccines (Basel). 2018;6:78. doi:10.3390/vaccines6040078.
   PubMed Web of Science ®Google Scholar
• Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G. Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. Curr Med Res Opin. 2018;34:1261–69. doi:10.1080/03007995.2017.1416347.
   PubMed Web of Science ®Google Scholar
• National quality forum. Priority setting for healthcare performance measurement: addressing performance measure gaps for adult immunizations. 2014. [accessed 2019 Apr 10]. https://www.qualityforum.org/Publications/2014/08/Priority_Setting_for_Healthcare_Performance_Measurement__Addressing_Performance_Measure_Gaps_for_Adult_Immunizations.aspx
   Google Scholar
• Shen AK, Groom AV, Leach DL, Bridges CB, Tsai AY, Tan L. A pathway to developing and testing quality measures aimed at improving adult vaccination rates in the United States. Vaccine. 2019;37:1277–83. doi:10.1016/j.vaccine.2019.01.044.
   PubMed Web of Science ®Google Scholar
• HEDIS 2020 Volume 2. Appendix 1: summary table of measures, product lines and changes. 2020. [accessed 2020 May 6]. https://www.ncqa.org/wp-content/uploads/2019/07/20190701_HEDIS_2020_Measures_Summary_of_Changes.pdf
   Google Scholar
• Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013;4:171.
   PubMed Web of Science ®Google Scholar
• Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32:5027–34. doi:10.1016/j.vaccine.2014.07.013.
   PubMed Web of Science ®Google Scholar
• Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases. J Infect Dis. 2018;218:347–54. doi:10.1093/infdis/jiy103.
   PubMed Web of Science ®Google Scholar
• Navarro-Torné A, Hanrahan F, Kerstiëns B, Aguar P,LM. Public health–driven research and innovation for next-generation influenza vaccines, European Union. Emerg Infect Dis. 2019;25(2). https://doi.org/10.3201/eid2502.180359
   Google Scholar
• Matanock A Considerations for PCV13 use among adults ≥65 years old and a summary of the evidence to recommendations framework. Advisory committee on immunization practices june 2019 meeting. 2019. [accessed 2019 Nov 13]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-06/Pneumococcal-2-Matanock-508.pdf
   Google Scholar
• Havers F. Tdap and Td: summary of Work Group considerations and proposed policy options. 2019. [accessed 2019 Dec 11]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-10/Pertussis-03-Havers-508.pdf
   Google Scholar